Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Um but again, if there's one takeaway, this ta this this our conversations about anti amyloid therapies and the biomarker transformation of Alzheimer's.
I urge my colleagues in geriatrics though, learn about late, L A T E horrible nickname.
N that's not a name, it's an acronym.
Limbic associated T D P encephalopathy.
I didn't make it up.
Yeah, what you don't know and
What we don't actually know is and what doesn't line up is is that change in brain volume reflecting neurodegeneration or not?
Because the neurodegeneration markers don't move in the direction of worsening neurodegeneration.
So your P tau is
um measures and other measures of neurodegeneration go in the direction that you've reduced neurodegeneration.
But yes, you're right, the MRI measures for atrophy don't go in that right direction.
I think it's a it's a question still to be studied.
But I can't I don't think the data say that is worsening neurodegeneration.
The data say that's the effect of the drug and removing amyloid
on brain volume and we haven't figured out what that means physiologically or pathophysiologically.
It's a very interesting but qu observation.
Yeah, well that I th you know they were for no, but the uh what do they call the Delphine?
Yeah.
So I think that's the conversation to have.
I think I think I s I'm seeing the field sort of go on either side on the doax.
Showing 301–320 of 1,378 · page 16 of 69
← Previous
Next →